1. EVALUATE EFFECTIVENESS OF GEFIITINIB IN FIRST LINE TREATIMENT AVANCED NSCLC PATIENTS WITH EGFR MUTATION
BS TRẦN THỊ CHUNG, Ths. NGUYỄN THỊ OANH
Oncology department, National Lung Hospital
This presentation is sponsored by AstraZeneca for scientific purpose

2. BACKGROUND Common cancer, NSCLC 80-85% EGFR and targeted therapy
Female, non-smoker, adenocarcinoma, Asian: 60-70%
National Lung Hospital: 2012

3. STUDY OBJECTIVES
Evaluate ORR
PFS, OS, side effects

4. SUBJECS 33 patients Stage IIIB, IV EGFR mutation on exon 19 or 21
National Lung Hospital from 2012 to 2015

5. ELIGIBLE CRITERIA Older than 18 yo Stage IIIB or IV
Mutation19 deletion or L858R/exon 21
At least 1 targeted lesion can evaluate according to RECIST criteria

6. EXCLUSION CRITERIA Stage I, II and IIIA
Wild-type or unknow EGFR mutation status

7. STUDY DESIGN
Retrospective description

8. RESULTS 1. Characteristics of study group Characteristics Group
Number of pts.(%)
Age
>= 60 yo
21(63,6%)
< 60 yo
12(36,6%)
Sex
Male
3 (20,1%)
Female
30(90,9%)
ECOG
0-1
26(78,8%)
2-3
7 (21,2)
Histology
Adenocarcinoma
33(100%)
Smoking status
Smoker
3 (9,1%)
Non-smoker
Mutation type
Exon 19 mutation
18(54,5%)
Exon 20 mutation
15(45,5%)
Stage
IIIB
7 (21,2%) IV
Total

9. RESULTS 2. Side effects Side effects Grade Grade 0 Grade 1 Grade 2
Skin rash
9(27,3%)
20(60,6%)
3(9,1%)
1(3%)
Oral mucosal imflammation
20(60,6)
12(36,4%)
Fatigue
26(78,8%)
7(21,2%)
Anorexia
27(81,8%)
6(18,2%)
Nail imflammation
24(72,7%)
8(24,3)
Diarrhea
2(82,4%)
6(17,6%)
Vomiting
4(18,2%)
Increased liver enzyme
32(97%)

10. RESULTS 3. Response rates Response type 3 months 6 months 9 months n %CR 4
12,1 3
9,1 PR 26
78,8 23
69,7 7
21,2 SD 2
6,1 16
48,5 PD 1
21,3
ORR( CR+PR) 30
90.9 27
87,1 18
30,3

11. Overall survival (months)
RESULTS
4. Overall survival
Overall survival (months)
Median
Shortest
Longest
PFS
11,9
1,6
42,3 OS
15,5
4,6
43,6

12. CONCLUSION
Gefitinib is effective in 1st line treatment advanced NSCLC with EGFR positive
High ORR, prolonged PFS and OS
Less side effects, improved quality of life